Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
Hamilton, Bermuda, April 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it will host its Full Year 2023 Financial Results and Business Update Call on Friday, April 10, 2024. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks followed by a Q&A session where they will address questions from investors and analysts.
百慕大汉密尔顿，2024年4月4日（GLOBE NEWSWIRE）——提供基于纳米颗粒技术的公司Altamira Therapeutics Ltd.（“Altamira” 或 “公司”）（纳斯达克股票代码：CYTO）今天宣布，将于2024年4月10日星期五举行2023年全年财务业绩和业务更新电话会议。创始人、董事长兼首席执行官托马斯·迈耶和首席运营官科瓦东加·帕内达将发表准备好的讲话，随后是问答环节，他们将回答投资者和分析师的问题。
Webcast Access:
网络直播接入：
- Event: Altamira Therapeutics Full Year 2023 Financial Results and Business Update Call
- Date: Wednesday, April 10, 2024
- Time: 8:30 am EDT
- Webcast URL: https://edge.media-server.com/mmc/p/ijjfu6tm
- 活动：Altamira Therapeutics 2023年全年财务业绩和业务更新电话会议
- 日期：2024 年 4 月 10 日星期三
- 时间：美国东部时间上午 8:30
- 网络直播网址： https://edge.media-server.com/mmc/p/ijjfu6tm
Registration for Call:
电话注册：
- Upon registering you will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details.
- Select a method for joining the call.
- Dial-In: A dial in number and unique PIN are displayed to connect directly from your phone.
- Call Me: Enter your phone number and click "Call Me" for an immediate callback from the system. The call will come from a US number.
- 注册后，您将收到拨入信息和用于加入通话的唯一 PIN 以及一封包含详细信息的确认电子邮件。
- 选择加入通话的方法。
- 拨入：显示拨入号码和唯一的 PIN，可直接从您的电话连接。
- 给我打电话：输入您的电话号码，然后单击 “给我打电话”，系统会立即进行回电。该电话将来自美国的号码。
A replay of the call will be available after the live event and accessible through the webcast link: https://edge.media-server.com/mmc/p/ijjfu6tm
电话会议将在直播结束后重播，可通过网络直播链接观看： https://edge.media-server.com/mmc/p/ijjfu6tm
About Altamira Therapeutics
关于阿尔塔米拉疗法
Altamira Therapeutics (Nasdaq: CYTO) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (OligoPhore / SemaPhore platforms). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a 49% stake (with additional economic rights) in its commercial-stage legacy asset Bentrio, an OTC nasal spray for allergic rhinitis. Further, the Company is in the process of partnering / divesting its inner ear legacy assets (AM-125 nasal spray for vertigo; post Phase 2; Keyzilen and Sonsuvi for tinnitus and hearing loss; Phase 3). Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: https://altamiratherapeutics.com
Altamira Therapeutics（纳斯达克股票代码：CYTO）正在开发和提供基于肽的纳米颗粒技术，用于将RNA高效输送到肝外组织（Oligophore/SemaPhore平台）。该公司目前有两个使用其专有交付技术的旗舰siRNA项目：用于KRAS驱动的癌症的 AM-401 和用于类风湿关节炎的 AM-411，均在体内概念验证以外的临床前开发中。多功能交付平台还适用于mRNA和其他 RNA 模式，并通过外包许可提供给制药或生物技术公司。此外，阿尔塔米拉持有其商业阶段遗留资产Bentrio49％的股份（还有额外的经济权利），Bentrio是一种治疗过敏性鼻炎的非处方鼻腔喷雾剂。此外，该公司正在合作/剥离其内耳遗留资产（用于眩晕的 AM-125 鼻腔喷雾剂；第二阶段后；Keyzilen和Sonsuvi用于耳鸣和听力损失；第三阶段）。Altamira成立于2003年，总部位于百慕大汉密尔顿，主要业务位于瑞士巴塞尔。欲了解更多信息，请访问：https://altamiratherapeutics.com
Investor Contact
Hear@altamiratherapeutics.com
译文内容由第三方软件翻译。